Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kartilage Cross is a visco-elastic gel designed for the treatment of knee osteoarthritis, developed and manufactured by Laboratoires Vivacy. It is an intra-articular injectable viscosupplement composed of highly purified, cross-linked (reticulated) hyaluronic acid of non-animal origin, formulated with mannitol as an antioxidant. The primary therapeutic action is the mechanical restoration of the rheological properties of synovial fluid, which improves joint lubrication and shock absorption. The inclusion of mannitol serves to scavenge free radicals and prevent the oxidative depolymerization of the hyaluronic acid chains, thereby increasing the residence time of the product within the joint and enabling a single-injection treatment regimen for symptomatic relief of pain and stiffness.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Kartilage Cross.